Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective

PURPOSE: Children and young adults with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) have poor survival due to ineffective therapy options. The newly approved chimeric antigen receptor T-cell (CAR-T) therapy, tisagenlecleucel, has demonstrated improved survival but at a high up-fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiao Jun, Wang, Yi-Ho, Ong, Matthew Jian Chun, Gkitzia, Christina, Soh, Shui Yen, Hwang, William Ying Khee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078873/
https://www.ncbi.nlm.nih.gov/pubmed/35535300
http://dx.doi.org/10.2147/CEOR.S355557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078873/
https://www.ncbi.nlm.nih.gov/pubmed/35535300
http://dx.doi.org/10.2147/CEOR.S355557

Ejemplares similares